We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
LMNL

Price
-
Stock movement up
+- (%)
Company name
Liminal BioSciences Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
27.62M
Ent value
18.63M
Price/Sales
56.14
Price/Book
1.29
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
78.03
Forward P/E
-
PEG
-
EPS growth
-
1 year return
88.89%
3 year return
-56.78%
5 year return
-71.14%
10 year return
-40.16%
Last updated: 2024-12-17

DIVIDENDS

LMNL does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E78.03
Price to OCF-
Price to FCF-
Price to EBITDA3.85
EV to EBITDA2.60

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales56.14
Price to Book1.29
EV to Sales37.87

FINANCIALS

Per share

Loading...
Per share data
Current share count3.25M
EPS (TTM)0.11
FCF per share (TTM)-11.64

Income statement

Loading...
Income statement data
Revenue (TTM)492.00K
Gross profit (TTM)492.00K
Operating income (TTM)-33.95M
Net income (TTM)354.00K
EPS (TTM)0.11
EPS (1y forward)-

Margins

Loading...
Margins data
Gross margin (TTM)100.00%
Operating margin (TTM)-6899.59%
Profit margin (TTM)71.95%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash19.31M
Net receivables788.00K
Total current assets25.64M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets31.80M
Accounts payable0.00
Short/Current long term debt1.21M
Total current liabilities9.24M
Total liabilities10.32M
Shareholder's equity21.48M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-36.12M
Capital expenditures (TTM)22.00K
Free cash flow (TTM)-36.12M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity1.65%
Return on Assets1.11%
Return on Invested Capital1.60%
Cash Return on Invested Capital-163.04%

STOCK INFORMATION

Downside potential

Loading...
Downside potential data
LMNLS&P500
Current price drop from All-time high-99.97%-10.85%
Highest price drop-99.99%-56.47%
Date of highest drop30 Dec 20229 Mar 2009
Avg drop from high-64.03%-11.07%
Avg time to new high38 days12 days
Max time to new high1837 days1805 days
COMPANY DETAILS
LMNL (Liminal BioSciences Inc) company logo
Marketcap
27.62M
Marketcap category
Small-cap
Description
Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
Employees
0
Investor relations
-
SEC filings
CEO
Kenneth Harry Galbraith
Country
USA
City
Laval
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner